Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
October 09, 2024
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Semaglutide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
China's First Biosimilar Ozempic Drug Applies for Approval
Details : Jiyoutai (semaglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Product Name : Jiyoutai
Product Type : Peptide
Upfront Cash : Inapplicable
April 03, 2024
Lead Product(s) : Semaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Semaglutide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
April 18, 2023
Lead Product(s) : Semaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Peking University Cancer Hospital & Institute | Second Affiliated Hospital, Zhejiang University | Jiangsu Cancer Institute & Hospital | The First Affiliated Hospital with Nanjing Medical
Deal Size : Inapplicable
Deal Type : Inapplicable
Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 07, 2013
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Peking University Cancer Hospital & Institute | Second Affiliated Hospital, Zhejiang University | Jiangsu Cancer Institute & Hospital | The First Affiliated Hospital with Nanjing Medical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics and Pharmacodynamics Study of Pegfilgrastim in Chemotherapy Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 11, 2012
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable